NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $73.91 -1.24 (-1.65%) (As of 11:08 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Dr. Reddy's Laboratories Stock (NYSE:RDY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RDY alerts:Sign Up Key Stats Today's Range$73.74▼$75.1550-Day Range$75.20▼$84.2152-Week Range$63.72▼$84.46Volume21,147 shsAverage Volume209,732 shsMarket Capitalization$12.34 billionP/E Ratio18.48Dividend Yield0.54%Price Target$87.00Consensus RatingHold Company OverviewDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Read More… Most People Are Dead Wrong. (Ad)Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.I call it my AI Retirement Playbook. I recommend you check it out now. Dr. Reddy's Laboratories Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks35th Percentile Overall ScoreRDY MarketRank™: Dr. Reddy's Laboratories scored higher than 35% of companies evaluated by MarketBeat, and ranked 812th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDr. Reddy's Laboratories has received no research coverage in the past 90 days.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth0.49% Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 0.49% in the coming year, from $4.11 to $4.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 18.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 18.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 137.39.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 1.73. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dr. Reddy's Laboratories' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.32% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 2.33%, indicating that investor sentiment is decreasing. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.52%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 9.93%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 9.69% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.32% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 2.33%, indicating that investor sentiment is decreasing. News and Social Media2.9 / 5News Sentiment0.22 News SentimentDr. Reddy's Laboratories has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Dr. Reddy's Laboratories this week, compared to 3 articles on an average week.Search Interest3 people have searched for RDY on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by InstitutionsOnly 14.02% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address RDY Stock News HeadlinesDr Reddy's Laboratories (NYSE:RDY) Stock Quotes, Forecast and News SummaryOctober 29 at 5:23 AM | benzinga.comDr. Reddy’s Launches Groundbreaking Drug in IndiaOctober 29 at 12:21 AM | markets.businessinsider.comMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.October 30, 2024 | Brownstone Research (Ad)Dr. Reddy's Laboratories rises Monday, still underperforms marketOctober 28 at 7:21 PM | marketwatch.comJourney Medical announces presentation of DFD-29 dataOctober 26, 2024 | markets.businessinsider.comDr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive YearOctober 25, 2024 | businesswire.comDr. Reddy's Laboratories Stock Scheduled to Split on Tuesday, November 5th (NYSE:RDY)October 24, 2024 | americanbankingnews.comDr. Reddy's Laboratories outperforms market despite losses on the dayOctober 17, 2024 | marketwatch.comSee More Headlines RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $69.58 at the beginning of the year. Since then, RDY stock has increased by 8.1% and is now trading at $75.20. View the best growth stocks for 2024 here. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Limited (NYSE:RDY) released its earnings results on Wednesday, January, 31st. The company reported $0.99 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.11. The business had revenue of $867 million for the quarter, compared to analyst estimates of $827.81 million. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 20.32% and a net margin of 19.28%. When did Dr. Reddy's Laboratories' stock split? Dr. Reddy's Laboratories's stock split on Tuesday, November 5th 2024. The 5-1 split was announced on Thursday, September 12th 2024. The newly minted shares will be issued to shareholders after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the split would have 500 shares after the split. Who are Dr. Reddy's Laboratories' major shareholders? Dr. Reddy's Laboratories' top institutional investors include Robeco Institutional Asset Management B.V. (1.24%), Allspring Global Investments Holdings LLC (0.06%), Creative Planning (0.06%) and Artemis Investment Management LLP (0.04%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings1/31/2024Today10/30/2024Next Earnings (Estimated)11/01/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:RDY CUSIPN/A CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees27,048Year Founded1984Price Target and Rating Average Stock Price Target$87.00 High Stock Price Target$87.00 Low Stock Price Target$87.00 Potential Upside/Downside+15.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$4.03 Trailing P/E Ratio18.80 Forward P/E Ratio18.30 P/E Growth1.73Net Income$668 million Net Margins19.28% Pretax Margin24.88% Return on Equity20.32% Return on Assets14.62% Debt Debt-to-Equity Ratio0.02 Current Ratio2.55 Quick Ratio1.90 Sales & Book Value Annual Sales$288.51 billion Price / Sales0.04 Cash Flow$4.84 per share Price / Cash Flow15.54 Book Value$20.17 per share Price / Book3.73Miscellaneous Outstanding Shares166,893,000Free Float163,601,000Market Cap$12.55 billion OptionableOptionable Beta0.55 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NYSE:RDY) was last updated on 10/30/2024 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | SponsoredThis biotech's ONE drug could change medicine as we know itThis Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses...Smallcaps Daily | Sponsored2 Pro Traders… 4 Livestreams… 4 Live TradesThe Zero Day Loophole: The Secret of HUGE Overnight Profits from Government ReportsMonument Traders Alliance | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.